RCT 58 hospitalized children with moderate COVID-19 showing shorter hospitalization and improved oxygen saturation with N-acetylcysteine treatment
Cagrilintide is a promising investigational peptide that has demonstrated favorable safety and tolerability profiles across multiple Phase 2 and Phase 3 clinical trials, including cardiac safety monitoring
Anea CB, Zhang M, Chen F, Ali MI, Hart CMM, Stepp DW, et al
Confidence That Lasts, Shield Against Damage Stop worrying about future flare-ups
For obese individuals with lymphedema, significant weight loss achieved through GLP-1 therapy may offer several advantages: Reduced mechanical load on compromised lymphatic vessels Decreased adipose tissue deposition in affected limbs Improved mobility and exercise tolerance, facilitating physical therapy Reduced systemic inflammation associated with obesity Enhanced quality of life through combined weight loss and symptom improvement Clinical guidelines from organizations such as the National Lymphedema Network and NCCN Survivorship Guidelines emphasize weight management as an important component of comprehensive lymphedema care for overweight patients
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans
